Dolutegravir Patent Expiry and a $2.5 Billion Survival Strategy

GSK has announced a three-year restructuring plan to reduce costs by approximately $2.5 billion (about £1.9 billion) annually, in response to the impending 2028-2030 patent expiry of dolutegravir, a key ingredient in its HIV treatment. Dolutegravir, which generated over $5 billion in revenue last year, is a core asset for GSK. The patent expiry will inevitably lead to a sharp decline in sales as cheaper generic drugs enter the market. This large-scale cost reduction is twice the amount anticipated by Jefferies analyst Michael Leuchten, and the market interprets it as a strong commitment from management to proactively absorb the impact of the patent cliff. Indeed, GSK's share price rose by about 4% immediately after the announcement, reflecting the market's positive response.

Reallocating Resources to Core Specialty Medicines Through Business Restructuring

The core of this restructuring is not just cost control, but a fundamental shift to reinvest the secured funds into the pipeline of high-value specialty medicines. GSK plans to introduce artificial intelligence (AI) technology comprehensively and streamline its supply chain and support departments to permanently reduce annual operating costs. The company will consolidate its existing research and development (R&D) hub in Stevenage, UK, and establish a new global center in Cambridge. It will also reduce non-core personnel and concentrate resources on priority research projects. This is considered part of a strategic roadmap to move away from traditional R&D methods and establish a digital technology-driven, high-efficiency drug development process.

Aggressive M&A and Successful Market Launch of New Drug Lineup

The new CEO, Luke Miels, has pledged to achieve annual revenue of £40 billion (approximately $52 billion) by 2031. To this end, the company has successfully completed large-scale mergers and acquisitions (M&A) and licensing agreements totaling approximately $16 billion in the past year. Notably, Jideytro (zidesamtinib), a ROS1-positive non-small cell lung cancer (NSCLC) treatment acquired from Nuvalent for $10.6 billion, received accelerated approval from the FDA on July 22, demonstrating its commercial success. In addition, ozureprubart, a food allergy treatment candidate acquired from RAPT Therapeutics for $2.2 billion, and HS235, a pulmonary arterial hypertension (PAH) treatment acquired from 35Pharma for $950 million, are in clinical development. These aggressive external acquisitions are expected to play a crucial role in diversifying away from the high dependence on dolutegravir and securing the next generation of growth drivers.

Expansion into MASH and Liver Disease Areas and Securing Future Value

GSK is actively expanding its territory beyond oncology and immunology into metabolic dysfunction-associated steatohepatitis (MASH) and metabolic disease treatment areas. Efimosfermin alfa, licensed from Boston Pharmaceuticals for an upfront payment of $1.2 billion, totaling $2 billion, is a promising FGF21 analog treatment that is about to enter Phase 3 clinical trials. This drug has a unique direct anti-fibrotic mechanism that differentiates it from existing MASH treatments, and if commercialized successfully, it will be a key weapon to address the significant unmet medical needs. GSK's agility in converting short-term restructuring pain into ammunition for securing future growth is expected to be a catalyst for re-rating the company's valuation in the medium to long term.